Expertly targeting drivers of cancer in select patient populations. June 2016
|
|
- Buck Morton
- 5 years ago
- Views:
Transcription
1 Expertly targeting drivers of cancer in select patient populations v June 2016
2 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, contain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve significant risks and uncertainties. For more detailed disclosures and discussions regarding such forward looking statements, please refer to Mirati s filings with the U.S. Securities and Exchange Commission ( SEC ), including without limitation Mirati s filings on Forms 10-K, 10-Q, and 8-K. Forward looking statements are based on the current expectations of management and upon what management believes to be reasonable assumptions based on information currently available to it. Such statements can usually be identified by the use of words such as "may," "would," "believe," "intend," "plan," "anticipate," "estimate," expect, and other similar terminology, or by statements that certain actions, events or results "may" or "would" be taken, occur or be achieved. Such statements include, but are not limited to, statements regarding Mirati s development plans and timelines, potential regulatory actions, expected use of cash resources, the timing and results of clinical trials, and the potential benefits of and markets for Mirati s product candidates. Forward looking statements involve significant risks and uncertainties and are neither a prediction nor a guarantee that future events or circumstances will occur. Such risks include, but are not limited to, potential delays in development timelines or negative clinical trial results, reliance on third parties for development efforts, changes in the competitive landscape, changes in the standard of care, as well as other risks described in Mirati s filings with the SEC. We are including this cautionary note to make applicable, and to take advantage of, the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forwardlooking statements. The information in this presentation is given as of the date above and Mirati expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. 2
3 We See Cancer v Differently
4 Successful Oncology Drug Development is not Linear Strong scientific rationale driven by continuous feedback to identify the best approach and support decision making DEEP scientific understanding and continual research to refine understanding of the disease and molecule IDENTIFYING oncogenic drivers or scientifically based combinations RELENTLESS focus on finding patients most likely to benefit from our medicines DESIGN trials that are adaptive and answer multiple questions in a single trial EMBRACE change and make real time adjustments to follow the data and the science as it emerges 4
5 Mirati s Leadership Team: Applying Proven Approaches to Oncology Development Charles M. Baum, M.D., Ph.D. CHIEF EXECUTIVE OFFICER SVP Clinical Research, Pfizer Leader of Key Oncology Programs: Ibrance, Xalkori, Sutent, Inlyta, Temodar Oncology Experience Isan Chen, M.D. CHIEF MEDICAL OFFICER CMO at Aragon Pharmaceuticals Previously VP at Pfizer with Ibrance, Xalkori, Sutent, Inlyta James Christensen, Ph.D. CHIEF SCIENTIFIC OFFICER Head of Precision Research, Oncology Research Unit, Pfizer Deep experience in precision oncology with Ibrance, Xalkori, Sutent, Inlyta Mark J. Gergen CHIEF OPERATIONS OFFICER SVP Corporate Development and Strategy at Amylin Pharmaceuticals Led sale to BMS for $7 Billion and $1B+ partnership with Takeda Mirati s leadership is supported by an operational team with deep oncology drug development expertise across all disciplines 5
6 Mirati s Clinical Programs Leveraging Clinical Assets in Multiple Settings Genetically Selected Populations in NSCLC* Improving Checkpoint Inhibitors in NSCLC Scientifically Based Expansion Opportunities Glesatinib Selected MET Alterations Combination with PD-1 MET & Axl in EGFR Resistance in combination with T790M in NSCLC Sitravatinib Phase 1b Selected RET, CHR4q12, CBL, Trk, DDR Alterations Combination with PD-1 Profile in combination with PD-1 in solid tumors Mocetinostat Combination with Durvalumab Combination with PD-1 All programs owned by Mirati except certain Asian rights to Mocetinostat Partnered with Taiho. *NSCLC = non-small cell lung cancer 6
7 Establishing Novel and Impactful Collaborations - Development of comprehensive companion diagnostics - - Proactive physician outreach for patients with targeted driver mutations - - Matching patients to targeted therapies and clinical trials - - Patient finding efforts underway and highly productive - Leader in tissue-based next-gen sequencing (NGS) using a comprehensive genomic profiling assay for solid tumors Tissue-based genomic profiling assay can detect all relevant mutations from one biopsy Utilizing NGS in circulating tumor DNA (ctdna) to identify multiple tumor mutations with a single blood sample Enables >30% of NSCLC patients who have insufficient tumor tissue for biopsy to be screened 7
8 v Glesatinib (MGCD265) Multi-Targeted Kinase Inhibitor
9 GLESATINIB Glesatinib: Leveraging Multiple Development Pathways Genetically Selected Populations in NSCLC Improving Checkpoint Inhibitors in NSCLC Scientifically Based Expansion Opportunities Glesatinib Selected MET Alterations Combination with PD-1 1b MET & Axl in in EGFR Resistance in in combination with T790M in in NSCLC Sitravatinib Phase 1b Selected RET, CHR4q12, CBL, Trk, DDR Alterations Combination with PD-1 Profile in combination with PD-1 in solid tumors Mocetinostat Combination with Durvalumab Combination with PD-1 9
10 GLESATINIB MET & Axl: Drivers of Solid Tumor Growth Targeting MET genetic alterations in NSCLC MET drives tumor growth when genetically altered High MET expression correlates with advanced stages of tumor progression and poor clinical outcomes MET gene amplification can result in resistance to EGFR inhibitors Genetic alterations in Axl reported in NSCLC Axl may be activated by gene amplification or rearrangement, resulting in oncogene addiction Axl is involved in the epithelial-mesenchymal transition (EMT) and is part of the TAM kinase family Increased expression of Axl has been observed in patients who are resistant to EGFR inhibitors in NSCLC 10
11 GLESATINIB A Selective Inhibitor of MET and Axl Single agent glesatinib targets 7-9% of NSCLC patients MET gene amplification 2-3% MET mutation 3-4% AXL gene amplification ~1% AXL rearrangement ~1% DRIVERS PREVALENCE ALK 4% MET MET mutations MET gene amplification 5 7% BRAF 4% AXL AXL rearrangements AXL gene amplification ~ 2% Other & Unknown 42% EGFR 15% KRAS 15% Kong Beltran et al Cancer Res 2006; Mitsudomi et al J Thoracic Oncol 2009; Seo et al Genome Res
12 GLESATINIB A Differentiated MET Inhibitor Glesatinib s Structure and Profile Confer Competitive Advantage Unique Profile Among MET Inhibitors MET Y1230C resistance mutant model Also inhibits Axl and TAM family More broadly active against MET mutations 100- to 1,000-fold greater activity than other MET inhibitors against some MET mutations Point Mutation MGCD265 AMG-208 crizotinib INC280 WT D1228H D1228N Y1230A Y1230C Y1230D Y1230H Y1235D May translate into activity against secondary mutations arising in treatment and avoiding acquired resistance Biochemical IC50s: < 100nM nM > 1000nM * Data on file, AACR 2016 Abstract 12
13 GLESATINIB Glesatinib Phase 1b Dose Expansion Selected MET and Axl Alteration NSCLC Patients* 10% 0% MET Amp MET Del MET Del MET Del MET Del MET Del MET Del MET Del MET Amp MET Del Axl Amp % -20% -30% % Phase1b data* demonstrates drug activity with durable confirmed responses and tumor regression -50% Confirmed PRs in 3 of 11 patients -60% Tumor regression in 10 of 11 patients Average duration -70% of response >39 weeks % Duration on Study (wks) * = ongoing Dose Interruption (I) Reduction (R) * * 56* I, R R (2) R I (5), R (2) R R I (3), R I (3), R R * data on file: as of May 20, 2016 represents NSCLC patients from Phase 1b with MET Amp and MET Exon 14 deletions similar to criteria and Axl amplification NSCLC patient 13
14 GLESATINIB Glesatinib Formulation Update trial utilizing new spray-dry dispersion (SDD) formulation Exposures comparable to the current formulation Improved tolerability reported in patients on the new formulation Decreased pill burden 3 SDD tablets from 7 soft gel capsules 2x daily Commercial formulation previously in development and discussed with FDA Patients in Phase1b and moving to new formulation *Phase 1b data as of May 20, 2016 in patients comparable to population **ASCO abstracts and presentations for INC280 (poster #9067) and crizotinib presentation (abtoract #108) 14
15 GLESATINIB Glesatinib Trial in NSCLC Progressing Tissue or blood NGS screen for patients with: MET mutations MET gene amplification NSCLC: MET mutations NSCLC: MET gene amplification Endpoints: Target Population: - Primary: Objective Response Rate (ORR) - Secondary: Progression Free Survival (PFS) - Recurrent or metastatic NSCLC patients with activating genetic alterations of MET, Open-label, single-agent trial Multi-national trial with up to 140 clinical sites Adaptive trial design has been discussed with FDA including formulation change with at least one prior treatment with a platinum-based combination therapy Dosing: 750mg BID SDD tablets Patients who started on original formulation will be switched 15
16 GLESATINIB Glesatinib: TAM May Enhance Checkpoint Inhibition TYRO, AXL and MERTK (TAM) are closely related family of kinases that regulate multiple stages in the cancer immunity cycle Low nanomolar inhibitor of Tyro, Axl and MERTK GAS-6 Axl TAM receptors create and maintain an immunosuppressive tumor micro environment GAS-6 Mer Protein S Inhibition of MERTK and Axl may lead to enhanced anti-tumor immunity MET inhibition may contribute by inhibiting Hepatic Growth Factor mediated immuno-suppression Axl saxl Mer GAS-6 Glesatinib clinical trial in combination with PD-1 planned in 2H
17 GLESATINIB Expansion Opportunity in MET & Axl: Important EGFR Resistance Mechanisms ALL TUMORS BECOME RESISTANT TO EGFR THERAPY Resistance mediated through alternative signaling pathways including MET and Axl Pre-clinical data validate EGFR and MET/Axl combo therapy to address therapeutic resistance Resistance to 3 rd generation EGFR RTK inhibitors may also be mediated by MET/Axl Clinical trial of glesatinib/t790 combination initiating in 2016 for targeted NSCLC patients Adapted from Gibbons, DL. Cancer Discov, 2014 Turke AB, et al. Cancer cell 17.1 (2010): , Zhang Z. et al. Nature Genetics 44.8 (2012): , Byers L.A., Diao L., Wang J., et al. Clinical Cancer Res 19. (2013): Published online first Oct. 22, 2012., Sequist L. et al. ASCO 2015 abstract, Efficacy of Rociletinib (CO-1686) in Plasma-genotyped T790m-positive NSCLC patients., Oxnard G, et al. ASCO 2015 poster #225, Preliminary Results of TATTON, a Multi-arm Phase 1b Trial of AZD9291 combined with MEDI4736, AZD6094 or Selumetinib in EGFR-mutant lung cancer. 17
18 v Sitravatinib (MGCD516) Multi-Targeted Kinase Inhibitor
19 SITRAVATINIB Sitravatinib Leveraging Multiple Development Pathways Genetically Selected Populations in NSCLC* Improving Checkpoint Inhibitors in NSCLC Scientifically Based Expansion Opportunities Glesatinib Selected MET Alterations Combination with PD-1 MET & Axl in EGFR Resistance in combination with T790M in NSCLC Sitravatinib Phase 1b Selected RET, CHR4q12, CBL, Trk, DDR Alterations Combination with PD-1 2 Phase 1b Profile in combination with PD-1 in solid tumors Mocetinostat Combination with Durvalumab Combination with PD-1 All programs owned by Mirati except certain Asian rights to Mocetinostat Partnered with Taiho. *non-small cell lung cancer 19
20 SITRAVATINIB A Novel Multi-Targeted Kinase Inhibitor Targeting Driver Mutations Single agent sitravatinib may target genetic alterations in up to 9% of NSCLC patients CHR4q12 gene amplification 3% CBL mutations 2.5% DRIVERS PREVALENCE IN NSCLC RET fusions 2% TrkA/C fusions TrkB/C mutations ~1% RET RET fusions 2% DDR2 mutations ~1% ALK 4% PDGFRA KIT, KDR CBL ET TRK CHR4q12 gene amplification CBL mutations TrkA/C fusions TrkB/C mutations 3% 2.5% ~1% Other & Unknown 42% EGFR 15% BRAF 4% DDR DDR2 mutations 1% KRAS 15% An et al 2012, Ding et al 2008, Doebele et al, 2014; Eguchi et al 1999, Euhus el al 2002, Greco et al 2010, Hammerman et al 2011, Harada et al 2011, Kohno et al 2012, Lipson et al 2012, Marchetti et al 2008, Phay et al 2010, Sheng et al 2001, TCGA 2014, Tan et al 2010, Ramos et al
21 SITRAVATINIB Sitravatinib Induces Tumor Regression and CRs Lung Cancer Models with Driver Alterations in RET, CH4q12, TRK a RET FUSION (KIF5B-RET) b CHR4q12 GENE AMPLIFICATION (PDGRFRA/KIT/KDR) c TRK FUSION (MPRIP-NTRK1) Vehicle MGCD516 20mg/kg QD Vehicle MGCD516 20mg/kg QD MGCD mg/kg (starting after day 14) MGCD mg/kg (starting after day 14) Start of treatment Tumor volume (mm 3 ) Tumor volume (mm 3 ) Start of treatment Tumor volume (mm 3 ) Start of treatment Percent Tumor Growth 300% 250% 200% 150% 100% 50% 0% Time (Days) Time (Days) -50% Time (Days) Preclinical data consistent with expectations for inhibition of driver mutations Plasma levels achieved in MGCD516 Phase 1 clinical trial are consistent with those in xenograft models that show tumor regression Doebele et al, 2015, IASLC World Conference on Lung Cancer 21
22 SITRAVATINIB Sitravatinib Phase 1b Expansion Trial Primary Focus NGS Screen for Patients with: RET fusions CHR4q12 amplicons CBL mutations DDR mutations TRK fusions/mutations NSCLC Other solid tumors Cohort 1 2nd-line or later NSCLC Cohort 2 2nd-line or later Basket (solid tumors) Solid tumors where sitravatinib may confer benefit Cohort 3 Advanced solid tumors Established recommended dose of 150 mg QD ClinTrials.gov identifier: NCT
23 SITRAVATINIB Sitravatinib: Early Signs of Clinical Activity Phase 1/1b Data 50% 40% 30% Best Response Target Lesions 20% 10% 0% AXL 7 copies 8 RET 10q11 # KDR 22 copies RET # 10q11 # # -10% -20% % % -50% -43 Bladder RCC NSCLC RCC Prostate = NSCLC with target genetic alteration = Other cancer type with target genetic alteration = RCC = Prostate * 2016 ASCO Poster #2575 Prostate Angiosarcoma NSCLC # = Patients continuing on study Assessments by investigator Prostate RCC 23
24 SITRAVATINIB Sitravatinib Phase 1/1b Data Presented at ASCO 2016 Encouraging Phase1b data Confirmed PR in heavily pre-treated mrcc patient 9 of 10 evaluable patients in Phase 1b demonstrated tumor regressions NSCLC patients with RET fusions showed tumor regressions Recommended dose of 150mg QD is generally well tolerated Study continues with plans to update data later this year Exploring potential of combination with checkpoint inhibitor * 2016 ASCO Poster #
25 Mocetinostat (MGCD103) v Spectrum Selective Class I & IV Histone Deacetylase (HDAC) Inhibitor
26 MOCETINOSTAT Mocetinostat Development with Immune Checkpoint Inhibitors Focus on Immunotherapy Combination Opportunity Genetically Selected Populations in NSCLC* Improving Checkpoint Inhibitors in NSCLC Scientifically Based Expansion Opportunities Glesatinib Selected MET Alterations Combination with PD-1 MET & Axl in EGFR Resistance in combination with T790M in NSCLC Sitravatinib Phase 1b Selected RET, CHR4q12, CBL, Trk, DDR Alterations Combination with PD-1 Profile in combination with PD-1 in solid tumors Mocetinostat Combination with Durvalumab in collaboration with Combination with PD-1 All programs owned by Mirati except certain Asian rights to Mocetinostat Partnered with Taiho. *non-small cell lung cancer 26
27 MOCETINOSTAT Mocetinostat May Enhance Efficacy of Immune Checkpoint Inhibitors (anti-pd-l1 and anti-pd-1) Mocetinostat Class I & IV HDAC Inhibitor Enhances anti-tumor efficacy when combined with immunotherapy by Increasing HLA expression and tumor immunogenicity Depleting regulatory T-cells and myeloidderived suppressor cells Increasing tumor PD-L1 expression (making tumors more likely to respond to checkpoint inhibitors) Does not inhibit Class II HDACs which may be immunosuppressive Maeda T, et al. Blood, vol. 96., Skov et al. Cancer Research, vol.65,2005., West AC et al. Cancer Res 2013., Kroesen M, et al. Oncotarget, vol. 5, 2014, Park, Jeenah et al. Epigenomics, 7(4) West AC et al. OncoImmunology 1:3. 27
28 Mocetinostat in Combination with Durvalumab (anti-pd-l1) Preclinical models demonstrate tumor regression Median Tumor Burden (mm 3 ) MOCETINOSTAT Dose schedule dependency study Significant reduction in tumor volume in the mocetinostat lead in group Mocetinostat single agent PD-L1 single agent Mocetinostat lead-in with PD-L1 added Days Post Tumor Implant 28
29 MOCETINOSTAT Mocetinostat + durvalumab Proof-of-Concept Trial in NSCLC Initiated Patient Entry Criteria Non-squamous histology Previous treatment with platinum doublet for advanced disease Failed PD-1 or PD-L1 inhibitors STAGE 1 N=9 Patients IF > 1 RESPONSES STAGE 2 N=17 Patients No/low PD-L1 expression (PD-L1 naive) STAGE 1 N=9 Patients IF > 1 RESPONSES STAGE 2 N=17 Patients High PD-L1 expression (PD-L1 naive) STAGE 1 N=17 Patients IF > 6 RESPONSES STAGE 2 N=44 Patients Study initiated and enrolling patients Potential to observe initial signals of activity by early 2017 * Trial includes dose lead /escalation to confirm tolerability of combination 29
30 Clinical Milestones Financials* Glesatinib MGCD265 Phase 1b Dose Expansion POC in NSCLC Trial in 2 nd Line NSCLC MET gene amplification and MET mutations PD-1 Combination POC in NSCLC T790M Combination POC in NSCLC Cash $108.0M Shares Outstanding 19.9M NASDAQ: MRTX Sitravatinib MGCD516 Phase 1b Expansion Trial in NSCLC & Solid Tumors Mocetinostat MGCD103 Trial in NSCLC mocetinostat w/ durvalumab (anti-pd-l1) * As of Mar 31,
31 vthank you
A targeted oncology company developing a pipeline of cancer therapies for select patient populations.
A targeted oncology company developing a pipeline of cancer therapies for select patient populations. JEFFERIES GLOBAL HEALTHCARE CONFERENCE CHARLES BAUM, M.D., PH.D., PRESIDENT AND CEO JUNE 2015 Safe
More informationA targeted oncology company developing a pipeline of cancer therapies for precisely defined patient populations.
A targeted oncology company developing a pipeline of cancer therapies for precisely defined patient populations. Jefferies 2014 Global Healthcare Conference JUNE 2014 Safe Harbor Statement Certain statements
More informationCorporate Presentation. November 2017
v Corporate Presentation November 2017 Safe Harbor Statement Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, contain
More informationTargeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation January 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationCORPORATE PRESENTATION
CORPORATE PRESENTATION June 2017 FORWARD LOOKING SAFE HARBOR STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationTargeting the genetic and immunological drivers of cancer
NASDAQ: MRTX Targeting the genetic and immunological drivers of cancer Corporate Presentation April 2019 1 Safe Harbor Statement Certain statements contained in this presentation, other than statements
More informationLeerink Immuno-Oncology Roundtable Conference
Leerink Immuno-Oncology Roundtable Conference September 28, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private
More informationDetermined to realize a future in which people with cancer live longer and better than ever before Q Conference Call
Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation
More informationArQule Jefferies Global Healthcare Conference June 2015
ArQule Jefferies Global Healthcare Conference June 2015 1 ArQule Corporate Update Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning
More informationArQule CorporateUpdate
ArQule April 2015 1 ArQule CorporateUpdate Safe Harbor This presentation and other statements by ArQule may contain forwardlooking statements within the meaning of the Private Securities Litigation Reform
More informationCombining HS-110 and anti-pd-1 in NSCLC. September 1, 2015
Combining HS-110 and anti-pd-1 in NSCLC September 1, 2015 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking
More informationLION. Corporate Presentation June 2016 BIOTECHNOLOGIES. Leadership & Innovation in Oncology
LION BIOTECHNOLOGIES Leadership & Innovation in Oncology Corporate Presentation June 2016 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private
More informationMore cancer patients are being treated with immunotherapy, but
Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 3Q 2018 EARNINGS PRESENTATION NOVEMBER 2018 1 Forward-looking statements disclosure This presentation
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2016 EARNINGS PRESENTATION MARCH 2017 1 Forward-looking statements disclosure This presentation contains
More informationWells Fargo Healthcare Conference September 6, 2018
Wells Fargo Healthcare Conference September 6, 2018 Safe Harbor Statement To the extent that statements contained in this presentation are not descriptions of historical facts regarding TESARO, they are
More informationSpectrum Pharmaceuticals
Spectrum Pharmaceuticals Joe Turgeon President and CEO June 2018 Investor Presentation 1 Safe Harbor Statement This presentation contains forward looking statements regarding future events and the future
More information33 rd Annual J.P. Morgan Healthcare Conference. January 2015
33 rd Annual J.P. Morgan Healthcare Conference January 2015 Forward-looking Statements This presentation contains forward-looking statements, which express the current beliefs and expectations of management.
More informationARQ 087 Overview. FGFR Inhibitor. March 2017
ARQ 087 Overview FGFR Inhibitor March 2017 Safe Harbor This presentation and other statements by ArQule contain forward-looking statements within the meaning of the Private Securities Litigation Reform
More informationCorporate Presentation March 2016
Corporate Presentation March 2016 Forward Looking Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.
More informationTARGET A BETTER NOW FORWARD-LOOKING STATEMENTS NASDAQ: IMGN. Current as of January 2018
NASDAQ: IMGN TARGET A BETTER NOW Current as of January 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward looking statements based on management's current expectations. These statements
More informationNewLink Genetics Corporation
Cantor Fitzgerald 2018 Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK October 3, 2018 Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking
More informationREWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES
REWRITING CANCER TREATMENT THROUGH EPIGENETIC MEDICINES May 18, 2017 Molecularly Defined Solid Tumor Program Update FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations,
More informationVeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
More informationFORWARD II PROGRAM UPDATE
FORWARD II PROGRAM UPDATE NASDAQ: IMGN May 17, 2018 FORWARD-LOOKING STATEMENTS This presentation includes forward-looking statements based on management's current expectations. These statements include,
More informationMarch Corporate Presentation
March 2017 Corporate Presentation Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationSyndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab)
Syndax Announces Updated Results from Phase 2 ENCORE 601 Trial of Entinostat in Combination with KEYTRUDA (pembrolizumab) Ongoing ENCORE 601 biomarker analyses suggest enhanced clinical benefit in subpopulation
More informationCorporate Presentation October 2018 Nasdaq: ADXS
Innovations in Immuno-Oncology Corporate Presentation October 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements
More informationRXDX-101 & RXDX-102. Justin Gainor, MD February 20 th, 2014
RXDX-101 & RXDX-102 Justin Gainor, MD February 20 th, 2014 Background Chromosomal fusions are important oncogenic drivers in NSCLC - ALK Rearrangements (4-6%) - ROS1 Rearrangements (1-2%) - RET Rearrangements
More informationDawson James Conference
Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding
More informationNew Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all
New Avenues for the development and evaluation of therapy: Complex, multi-pronged, not one size fitting all Antoine Yver MD MSC Senior VP & Head Oncology Global Medicines Development AstraZeneca, Gaithersburg
More informationAVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET
NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)
More informationJune IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs)
June 2015 IMMUNE DESIGN The in vivo generation of cytotoxic CD8 T cells (CTLs) 1 Forward-looking Statements This presentation contains forward-looking statements with respect to, among other things, our
More informationInarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018
Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities
More informationOncology Therapeutics without Compromise APRIL 2011
Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other
More informationLeading the Next Wave of Biotech Breakthroughs
Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive
More informationJuly, ArQule, Inc.
July, 2012 Safe Harbor This presentation and other statements by ArQule may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to clinical
More informationInvestor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer.
Investor Webcast: Initial Data from Phase 1a/1b Trial of Cabiralizumab/OPDIVO and Early Efficacy Signal in Pancreatic Cancer November 8, 2017 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation
More informationMerck ASCO 2015 Investor Briefing
Merck ASCO 2015 Investor Briefing Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation
More informationFive Prime Therapeutics, Inc. Corporate Overview
Five Prime Therapeutics, Inc. Corporate Overview June 2015 NASDAQ:FPRX Forward-Looking Statements Disclaimer This presentation contains forward-looking statements within the meaning of the Private Securities
More informationDetermined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019
Determined to realize a future in which people with cancer live longer and better than ever before 4Q18 EARNINGS PRESENTATION MARCH 2019 Forward-looking statements disclosure This presentation contains
More informationSavolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer
Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study
More information2016 Year-End Results and Conference Call. March 14, 2017
2016 Year-End Results and Conference Call March 14, 2017 Forward Looking Statement This communication contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform
More informationInvestor Presentation
Investor Presentation June 2017 Joe Turgeon President and Chief Operating Officer Safe Harbor Statement This presentation contains forward-looking statements regarding future events and the future performance
More informationNewLink Genetics Corporation
Cantor Fitzgerald Global Healthcare Conference NewLink Genetics Corporation NASDAQ: NLNK September 25, 2017 Forward-Looking Disclaimer This presentation contains forward-looking statements of NewLink that
More informationAVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer
FOR IMMEDIATE RELEASE AVEO and Astellas Announce TAURUS Patient Preference Clinical Study Comparing Tivozanib with Sunitinib in First-Line Kidney Cancer Study designed to build upon safety profile demonstrated
More informationCorporate Presentation May Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers
Corporate Presentation May 2016 Transforming Immuno-Oncology Using Next-Generation Immune Cell Engagers Forward-looking statements / safe harbor This presentation and the accompanying oral commentary contain
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More informationAVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC
FOR IMMEDIATE RELEASE AVEO and Astellas Announce Positive Findings from TIVO-1 Superiority Study of Tivozanib in First-Line Advanced RCC - Tivozanib is the First Agent to Demonstrate Greater than One Year
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationCorporate Presentation September Nasdaq: ADXS
Corporate Presentation September 2018 Nasdaq: ADXS Forward-Looking Statements This presentation contains forward-looking statements, including, but not limited to, statements regarding the ability and
More informationNational Bank 8th Annual Quebec Conference TSX: IMV. May 30, IMV Inc. All rights reserved.
National Bank 8th Annual Quebec Conference TSX: IMV May 30, 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV Inc.
More informationAVEO and Astellas Report Final Overall Survival Results from TIVO-1
AVEO and Astellas Report Final Overall Survival Results from TIVO-1 - Median Overall Survival of 28.8 Months Reported for Tivozanib in Patients with Advanced Kidney Cancer - CAMBRIDGE, Mass. and TOKYO,
More informationFull Year 2017 Financial Results. February 14, 2018
Full Year 2017 Financial Results February 14, 2018 Agios Conference Call Participants Prepared Remarks Introduction KENDRA ADAMS, Sr. Director, Investor Relations 2018 Vision & Key Milestones DAVID SCHENKEIN,
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationCelldex Provides Corporate Update and Reports First Quarter 2018 Results
May 10, 2018 Celldex Provides Corporate Update and Reports First Quarter 2018 Results HAMPTON, N.J., May 10, 2018 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported business and
More informationMANIFEST Phase 2 Enhancement / Expansion
MANIFEST Phase 2 Enhancement / Expansion Investor Conference Call Stellar Science, Breakthrough Medicine October 11, 2018 Forward-Looking Statements This presentation contains forward-looking statements
More informationMECHANISMS OF 1ST GENERATION RESISTANCE. Byoung Chul Cho, M.D., Ph.D.
MECHANISMS OF 1ST GENERATION RESISTANCE Byoung Chul Cho, M.D., Ph.D. CONFLICT OF INTEREST Research funding: Novartis, Bayer, AstraZeneca, MOGAM Institute, Dong-A ST Consulting role: Novartis, AstraZeneca,
More informationRob Ross, MD. Infinity Pharmaceuticals March 9 th, 2011
Heat Shock Protein 90 (Hsp90) Inhibition as a Potential Novel Approach to the Treatment of Patients with ALK Mutated Non-small Cell Lung Cancer (NSCLC) Rob Ross, MD Infinity Pharmaceuticals March 9 th,
More informationUpdated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment with Targeted Tyrosine Kinase Inhibitors
Q: How is the strength of recommendation determined in the new molecular testing guideline? A: The strength of recommendation is determined by the strength of the available data (evidence). Strong Recommendation:
More informationCorporate Overview May 8, 2014
0 Corporate Overview May 8, 2014 NASDAQ: CRIS Forward Looking Statements This presentation contains statements about Curis future expectations, plans and prospects that constitute forward-looking statements
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationNCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
More informationDynavax Corporate Presentation
Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,
More informationNY-ESO SPEAR T-cells in Synovial Sarcoma
NY-ESO SPEAR T-cells in Synovial Sarcoma ASCO Update June 6, 2017 Disclaimer This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform
More informationTargeting the Tumor Locally
ARMING THE IMMUNE SYSTEM TO FIGHT CANCER Targeting the Tumor Locally October 2017 NASDAQ:ONCS Cautionary Note Regarding Forward-Looking Statements To the extent statements contained in the following presentations
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 1Q 2018 EARNINGS PRESENTATION MAY 2018 1 Forward-looking statements disclosure This presentation contains
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationAnnounce Expected Initiation of an Investigator-Initiated, Randomized, Phase 2, Multicenter Trial of Ficlatuzumab and Cetuximab in HNSCC in 2H 2017
AVEO Oncology and Biodesix Announce Results from Two Investigator-Sponsored Phase 1 Studies of HGF Targeted Antibody Ficlatuzumab at the 2017 ASCO Annual Meeting Announce Expected Initiation of an Investigator-Initiated,
More informationInvestor Call. May 19, Nasdaq: IMGN
Investor Call May 19, 2017 Nasdaq: IMGN Forward-Looking Statements This presentation includes forward-looking statements based on management's current expectations. These statements include, but are not
More informationPLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective
PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective Davy Chiodin, VP - Regulatory Science, QA and Compliance, Acerta Pharma (A Member of the AstraZeneca
More informationTHE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER. Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium
THE FUTURE OF IMMUNOTHERAPY IN COLORECTAL CANCER Prof. Dr. Hans Prenen, MD, PhD Oncology Department University Hospital Antwerp, Belgium DISCLAIMER Please note: The views expressed within this presentation
More informationInducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy
Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking
More informationStifel Healthcare Conference John Scarlett, M.D. Chief Executive Officer November 19, 2014
Stifel Healthcare Conference 2014 John Scarlett, M.D. Chief Executive Officer November 19, 2014 1 forward-looking statements Except for statements of historical fact, the statements during this presentation
More informationCorporate Presentation
Corporate Presentation Leerink Global Healthcare Conference February 14 th -15 th, 2018 C O N F I D E N T I A L a n d P R O P R I E T A R Y Forward Looking Statements / Safe Harbor This presentation contains
More informationJefferies 2016 Healthcare Conference. Reid Huber, PhD Chief Scientific Officer
Jefferies 2016 Healthcare Conference Reid Huber, PhD Chief Scientific Officer June 8, 2016 Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this
More informationOTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento
OTRAS TERAPIAS BIOLÓGICAS EN CPNM: Selección y Secuencia Óptima del Tratamiento Dolores Isla Servicio de Oncología Médica HCU Lozano Besa de Zaragoza 2008 Selection Factors in Advanced NSCLC ( 8y ago)
More informationTranslating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018
CYC 682 Translating cancer biology into medicines BIO CEO Investor Conference NASDAQ CYCC - February 12, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of the
More informationPersonalized Therapeutics The Power of Epigenetics. Company Overview. June 2014
Personalized Therapeutics The Power of Epigenetics Company Overview June 2014 2013 Accomplishments Forward Looking Statements This presentation contains forward-looking statements that involve substantial
More informationCorporate Presentation: Jefferies Global Healthcare Conference June 7, 2018
Corporate Presentation: Jefferies Global Healthcare Conference June 7, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More informationTranslating cancer biology into medicines Noble Capital Markets Conference NASDAQ CYCC - January 30, 2018
CYC 682 Translating cancer biology into medicines Noble Capital Markets Conference NASDAQ CYCC - January 30, 2018 Disclaimer This presentation contains forward-looking statements within the meaning of
More informationGiorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
More informationDetermined to realize a future in which people with cancer live longer and better than ever before
Determined to realize a future in which people with cancer live longer and better than ever before 4Q 2017 EARNINGS PRESENTATION MARCH 2018 1 Forward-looking statements disclosure This presentation contains
More informationARIAD Pharmaceuticals, Inc.
ARIAD Pharmaceuticals, Inc. June 8, 2016 David Sachs Non-small cell lung cancer 1 ARIAD clinical trial patient Some of the statements in this presentation constitute forward looking statements under the
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More informationG1 Corporate Overview March 11, 2019
G1 Corporate Overview March 11, 2019 www.g1therapeutics.com NASDAQ: GTHX 1 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements within the
More informationPath to Value and Profitability
Path to Value and Profitability June 4, 2015 Tim Clackson, Ph.D. President of R&D, Chief Scientific Officer ARIAD Pharmaceuticals, Inc. Elsa So Non-small cell lung cancer ARIAD clinical trial patient Some
More informationASCO 2017 WEBCAST. Elacestrant (RAD1901) June, 4, 2017
ASCO 2017 WEBCAST Elacestrant (RAD1901) June, 4, 2017 NASDAQ: RDUS Disclaimer: RAD1901 is an investigational agent Please refer to the ASCO 2017 poster for complete details Safe Harbor Any statements made
More informationASCO 2018 Investor Meeting
ASCO 2018 Investor Meeting June 4, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking statements for
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationBank of America Merrill Lynch 2018 Health Care Conference. Reinventing Therapeutic Antibodies for the Treatment of Cancer
Bank of America Merrill Lynch 2018 Health Care Conference Reinventing Therapeutic Antibodies for the Treatment of Cancer May 17, 2018 1 Forward Looking Statements Special Note Regarding Forward-Looking
More informationASCO Highlights and Controversies in advanced Lung Cancer. Torino, 11 giugno 2015
ASCO 2015 Highlights and Controversies in advanced Lung Cancer Torino, 11 giugno 2015 Paolo Bironzo AOU S Luigi Gonzaga - Orbassano Scuola di Specializzazione in Oncologia Medica Università di Torino What
More informationCompany Overview. April Rewriting cancer treatment NASDAQ: EPZM
Company Overview NASDAQ: EPZM Rewriting cancer treatment Forward Looking Statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform
More informationNOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A. C5aR. NKp46 HALF-YEAR RESULTS. Tumor antigen KIR3DL2 CD39 MICA/B CD73 SEPTEMBER 18, 2017
NOVEL CHECKPOINTS IN IMMUNO-ONCOLOGY KIR NKG2A NKp46 C5aR Tumor antigen HALF-YEAR RESULTS KIR3DL2 MICA/B CD73 CD39 SEPTEMBER 18, 2017 Page 2 FORWARD LOOKING STATEMENT This document has been prepared by
More informationRevolutionizing the Treatment of Cancer
Revolutionizing the Treatment of Cancer January 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationCorporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
Corporate Presentation: 2018 Wedbush PacGrow Healthcare Conference August 14, 2018 2018 CytomX Therapeutics, Inc. 1 Forward Looking Statements Special Note Regarding Forward-Looking Statements This presentation
More information